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The goal governing dosage sched-
ules for the chemotherapy of gas-
trointestinal cancer has been, in 
general , to induce significant drug 
toxicity in order to insure maxi-
mum therapeutic effect. The pur-
suit of maximum therapeutic effect 
led logically to the development of 
"Life Islands" which permit the iso-
lated, relatively germ-free care of 
patients treated with intensive chem-
otherapy. However, intensive chem-
otherapy may have deleterious ef-
fects on patients other than that of 
increased susceptibility to infection. 
It is, therefore, important to be 
aware of the alternative approaches 
implied in a recent analysis of data 
obtained from the Eastern Clinical 
Drug Evaluation Program ( CDEP) . 
In this cooperative study, Bross et 
al. (1966a, b, c) have shown that 
patients manifesting drug toxicity 
do not necessarily show a greater 
frequency of tumor regression than 
do patients without toxicity. 
In the CDEP program a total of 
956 patients were treated with 5-
fluorouracil ( 5-FU), dimethylure-
thamine (AB-132), mitomycin C, 
chlorambucil , and 6-mercaptopu-
rine (6-MP) in a 60-day study of 
objective response. There was no 
increase in tumor response with 
high toxicity scores. In fact, the 
patients with the greatest toxicity 
showed a somewhat lower tumor 
response. These data (Ausman, 
1965; 1966; Bross, 1965; Bross et 
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al., 1966a, b, c) suggest that overt 
toxicity may not always be neces-
sary to obtain an oncolytic effect. 
This is further supported by a re-
cent study of the Eastern Solid Tu-
mor Group which compared 5-FU, 
fluorodeoxyuridine (FUDR), and 
methotrexate (MTX) at dose levels 
producing comparable toxicity in 
a group of patients with colon-rec-
tal and breast cancer (Hall, in 
press; Schneiderman and Krant, 
1966). With increased toxicity a 
plateau was reached beyond which 
no significant further regression of 
tumor could be obtained, and sur-
vival , despite tumor response, was 
shortened in comparison to those 
patients showing tumor response 
but minimal drug toxicity (fig. 1) . 
These observations as well as 
those of Ansfield ( 1964) and others 
(Cudmore and Groesbeck, 1964; 
Groesbeck and Cudmore, 1963) 
are supported by animal data 
(Louis, 1965) and suggest that it 
is not necessary to take patients to 
toxic drug levels to achieve a sig-
nificant remission. Such data should 
reinforce our awareness of the pos-
sible deleterious effects of drug ac-
tion on survival and remind us that 
the gain afforded by tumor regres-
sion can be lost in the morbidity 
and mortality induced by drugs. 
The Eastern CDEP data suggest 
that 5-FU and mitomycin C can 
produce significant therapeutic ef-
fects without severe toxicity (Aus-
man, 1965; 1966; Bross, 1965; 
Bross et al., 1966a, b, c). There-
fore, it is important to avoid severe 
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diarrhea, stomatitis, and marrow 
depressions with white counts be-
low 3,000/ mms or platelet counts 
below 75,000/ mm3• When used this 
way, 5-FU becomes of more gen-
eral clinical usefulness in gastroin-
testinal cancer. 
A renewed interest in alkylating 
agents has resulted from observa-
tions indicating objective tumor re-
gression ( > 50 % shrinkage) in 
colon-rectal cancer with AB-132 (8 
of 33), gastric cancer with AB-132 
and chlorambucil ( 6 of 26), and 
pancreatic cancer with AB-132 and 
chlorambucil ( 6 of 8) in a study 
by the Eastern CDEP (Ausman, 
1965; 1966; Bross, 1965; Bross et 
al., 1966a, b, c). 
Chlorambucil showed no activity 
in 15 patients with rectal cancer, 
while 5of12 responded toAB-132. 
Chlorambucil was given by mouth 
and appeared to be most effective 
in the upper gastrointestinal tract. 
Unfortunately, this study as per-
formed by the Eastern CDEP was 
non-comparative and limited to 
only two months of observation in 
ambulatory patients. More critical 
studies of these agents need to be 
done. In the meantime, the ease 
with which chlorambucil can be 
given makes it worthy of serious 





gastric and pancreatic cancer, al-
though its superiority to other alky-
lating agents has not been clearly 
shown. Similarly, AB-132 or an-
other parenteral alkylating agent 
can be used in colon-rectal cancer. 
Chemotherapy Combined 
with Surgical Treatment 
Laboratory evidence has sup-
ported the usefulness of adjuvant 
prophylactic chemotherapy at the 
time of surgery in the absence of 
known disease. However, the clini-
cal applications of this evidence 
have shown puzzling results. There 
is no improvement in recurrence 
rates in men with colon-rectal can-
cer who received high-dose thio-
TEP A (0.8 mg/kg) at the time of 
surgery, although women show a 
significantly increased survival time 
(U.C.L.A. Statistical Unit, 1965) . 
In this study a high dose, with its 
increased mortality and morbidity, 
was felt necessary. Fluorodeoxyuri-
dine (FUDR) used as an adjuvant 
by the Veterans Administration 
study shows no significant differ-
ence in recurrence rate at 30 
months (personal communication, 
M. W. Wolcott, 1965). These 
studies await simultaneous controls 
but evidence supports the possibility 
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Fig. 1-Colon and rectum cancer. Eastern group double blind, 3 drug study (all 
drugs combined). Data and graph courtesy of M.A. Schneiderman, M. J. Krant, 
and T. C. Hall of the Eastern Solid Tumor Group. A major portion of this data 
was presented in Cancer Chemotherapy Rept. 50: 107-112, 1966. 
that repeated 5-FU administration 
increases the survival of patients 
with occult tumor left behind. 
Recently, Mackman and Curreri 
( 1967) reported the results of a 
"second-look procedure" evaluating 
patients who had curative resections 
for colon cancer but who showed 
positive mesenteric node or serosal 
involvement at the time of "cura-
tive" resection. Post-operatively, 
these patients were given 5-fluor-
ouracil for four or more courses 
prior to their "second-look," one 
year post operatively. Twenty pa-
tients were examined, 17 of which 
had no tumor at the end of this one-
year period. An additional 11 pa-
tients who had direct extension to 
adjacent organs or structures, who 
were treated with only palliative 
resection, were examined following 
four to 10 courses of 5-fluorouracil. 
Seven of these patients were free of 
tumor, and three had tumor which 
was removed for possible "cure." 
This experience has recently been 
supported by a report by Rousselot 
et al. (1967, in press) who have re-
ported on the survival of patients 
over a five-year period following 
the effectiveness of both intralumi-
nal 5-fluorouracil administration 
and systemic intravenous 5-fluorou-
racil in the post-ope.rative period. 
This was a comparative study be-
tween nitrogen mustard and 5-fluo-
rouracil. Adjuvant nitrogen mustard 
had no effect on statistics regarding 
recurrence rate. However, for 5-
fluorouracil in those patients who 
had nodes (stage 3) significant im-
provement appeared. At five years 
the survival rates were 65% for 
the 5-fluorouracil treated versus 
32% in a nationwide control series 
and 26% in the St. Vincent's Hos-
pital control series. There was no 
apparent imorovement in survival 
rates in st:ige 1 and 2 colon cancer 
cases (negative nodes) as compared 
to those seen on the basis of the 
nationwide avernges and this re-
flects the over all effectiveness of 
surgery in earlv colon cancer. 
These studies despite the lack of 
concomitant controls point out the 
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possible usefulness of an adjuvant 
drug in the treatment of colon car-
cinoma particularly when known 
tumor is left behind. 
The value of massive intermittent 
chemotherapy in the absence of 
clinical disease as applied to acute 
leukemia is a proven one (Hanan-
ian, Holland, and Sheehe, 1965), 
but proof of an analogous situation 
in colon-rectal cancer is only sug-
gestive and requires further data. 
A study of this kind for gastric and 
bowel cancer using repeated courses 
of cytoxan or mitomycin C is being 
conducted in Europe (Karrer, 
I 964a and b), and the results 
should be of great interest when 
they become available. 
Wood et al. ( 1961) and others 
(Cliffton and Agostino, 1963; 
Koike, 1964) found a decrease in 
the viability of circulating tumor 
cells following the administration of 
fibrinolysins or anticoagulants. The 
adjuvant anti-tumor action of anti-
coagulants has not been explored 
at the clinical level, but there are 
controversial retrospective epidemi-
ological data that suggest that can-
cer patients who received antico-
agulants for post-surgical phlebitis 
or coronary disease may have 
shown an increase in tumor-free 
survival time (Michaels, 1964) . 
Based on this evidence, a study us-
ing heparin or fibrinolysin in the 
postoperative period deserves seri-
ous consideration. 
Regional perfusion has limited 
value except in very special cases 
(e.g., primary or metastatic disease 
to liver) and may not offer more 
palliation than is produced by sys-
temic drug administration. How-
ever, the aggressive approach of 
repeated intra-arterial administra-
tion of cytoxan and 5-FU by Bier-
man's group (Mesler, Winer, and 
Bierman, 1965) deserves closer at-
tention as does the work of Sulli-
van et al. (196'i) on prolonged 
intra-arterial infusions. 
The frequency of cancer cell 
seeding in abdominal wounds has 
led to the development of animal 
screening methods to develop ef-
fective agents for wound irrigation 
that would kill tumor cells. The 
clinical use of monoxychlorosene 
(Chlorpactin XCB) and mechlore-
thamine (HN,) and Thiotepa 
(TSPA) followed on these obser-
vations. Despite the demonstrated 
optimal activity of Na Hypoch-
lorite and HN, as tumorcidal agents 
in an animal tumor implantation 
screen, long-term follow-up of head 
and neck cancer patients receiving 
post-operative wound irrigation with 
these agents has shown accelerated 
tumor take in the irrigated area 
when compared to wound washing 
with normal saline (Mukhtar et al., 
1963). More recent five-year sur-
vival data fully supports these ob-
servations. These studies indicate 
that so called "topical chemother-
apy" or "cytocidal wound irriga-
tion" and should be absolutely con-
traindicated in the treatment of 
gastrointestinal cancer until long 
term follow-up indicates the ef-
ficacy of newer agents. 
Radiotherapy Adjuvant 
Chemotherapy 
Radiotherapy in combination 
with chemotherapy for synergistic 
or additive effect has a valid ra-
tionale, based on data of responsive 
animal tumors, when combined 
with AB-132 (Regelson and Pier-
ucci, 1964), 5-FU (Heidelberger 
and Ansfield, 1963; Baclesse, Du-
plan, and Romer, 1964), or mito-
mycin C (Baclesse et al., 1964). 
Results from past clinical studies 
of this type are difficult to analyze 
owing to the absence of concomit-
ant controls. Jn addition, such large 
doses of both drugs and radiation 
were used that the therapeutic gain 
possible through a more judicious 
selection of dosage levels may have 
been lost. One cannot expect pa-
tients with advanced cancer to 
show increased survival time when 
treated with comhinations of radia-
tion or drugs that would result in 
severe debilitation from either 
agent alone. Despite these difficul-
ties there are reports of increased 
survival for patients with cancer of 
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the pancreas or stomach treated 
with 5-FU in conjunction with 
radiation (Moertel et al., 1965). 
The current Veterans Administra-
tion long-term continued study 
which uses combinations of FUDR 
with radiation may give a more 
definitive answer, but systemic or 
local effects on host resistance 
could nullify the anti-tumor effect. 
New Approaches to 
Chemotherapy 
Of particular interest are drug 
combinations which may act syner-
gistically or additively by interfer-
ing with alternative metabolic 
pathways to eliminate the resistant 
tumor population. Most of the stud-
ies reported so far are preliminary 
and have not unequivocally dem-
onstrated the virtues of combina-
tion chemotherapy in gastrointesti-
nal cancer over the action of single 
agents. A report of regression in a 
pancreatic and epidermoid cancer 
with the combination of 6-thio-
guanine with duazomycin A is en-
couraging and is based on sound ra-
tionale (Lefkowitz et al. , 1965) . 
Animal data in the area of col-
lateral sensitivity has not been sys-
tematically applied to human tu-
mors. The results of one collateral 
sensitivity study that could be ap-
plied immediately demonstrated that 
a 5-FU resistant tumor in rodents 
showed increased response to alky-
lating agents (Rutman, 1964). To 
my knowledge this observation, 
which calls for the use of an alky-
lating agent after failure to respond 
to 5-FU, has not been tested 
clinically. Similarly, there are 
laboratory observations that uracil 
mustard makes transplanted Sar-
coma-180 tumor cells in mice more 
sensitive to the anti-tumor action 
of 6-thioguanine (Booth, Creasey, 
and Sartorelli, 1964). Reports of 
synergistic inhibition of S-180 by 
mitomycin C and 6-thioguanine or 
5-FU (Sartorelli and Booth, 1964) 
are also clinically interesting, since 
the clinical pharmacology of these 
agents is well known. 
A study is warranted on the use 
of methotrexate in 5-FU resistant 
patients based on the hypothesis 
that the resistant tumor may be de-
pendent on a de novo pathway of 
thymidylate synthesis (Welch, 
1963). However, Weiss and Jack-
son (1961) gave patients with gas-
trointestinal tract cancer MTX ( 5 
mg orally per day) following 5-FU 
and found no evident therapeutic 
gain. More recently evidence has 
accrued that MTX can increase the 
level of thymidylate synthetase in 
human leukemia (Roberts, 1966) . 
Thus pretreatment with MTX may 
deleteriously effect the response of 
tumor cells to 5-FU. 
Suitable for more immediate 
study is the verification of suggested 
evidence in man that glucose en-
hances 5-FU therapeutic effect 
(Gotto, Belkhode, and Touster, 
1964; Kessel , 1966; Lemon et al. , 
1963). lnosine (Gotto et al., 1964) 
or adenosine (Kessel, 1966) also 
results in increased tumor-cell up-
take of 5-FU. These observations 
may have clinical bearing and 
should be tested in comparative 
studies. 
The importance of varied dosage 
regimens is seen in the observations 
that the prolonged intravenous ad-
ministration of 5-FU is less toxic 
than rapid drug administration. 
However, any therapeutic gains 
from prolonged infusion may be 
offset by the convenience of rapid 
intravenous injection and greater 
control of dosage. Moertel et al. 
(1964) have found no improve-
ment in therapeutic results with 
5-FU in prolonged intravenous ad-
ministration as opposed to the 
single rapid daily loading program. 
Similar anti-tumor results, but with 
considerable decrease in toxicity, 
have now been observed clinically 
by Ansfield (1964) using 12 mg/ 
kg/ day for four days as compared 
to the earlier program of 15 mg/ 
kg/ day for four days, and the lower 
dose should clearly be the one of 
choice. Furthermore, the selection 
of patients for treatment with 5-FU 
should exclude severely debilitated 
patients, since such patients show a 
decreased drug tolerance. This is 
supported by data in the nutrition-
ally deprived rat (Wolberg and 
Curreri, 1960). In using 5-FU, it 
is well to remember that reports of 
a high order of regression such as 
that of Vaitkevicius et al. ( 1961) , 
objective regression in 20 of 55 pa-
tients with adenocarcinoma of the 
large bowel, are tempered by the 
observation that regression was 
clinically worthwhile in a small pro-
portion and even that occurred at 
the expense of severe toxicity in 
many patients. However, as dis-
cussed earlier, the evidence that re-
sponses can be seen in the absence 
of discomforting clinical toxicity or 
serious hematopoietic depression in-
dicates that 5-FU might be given 
to advanced cancer patients for 
shorter periods and at lower dosage 
to avoid toxicity. In such a study 
Young et al. (1960) obtained re-
sponses in 10% to 15 % of pa-
tients with bowel cancer with total 
dosage ranging from 30 to 150 mg/ 
kg. Similar results have been ob-
tained by Ansfield ( 1964) and oth-
ers (Cudmore and Groesbeck, 
1964). 
The topical administration of 
5-FU in a 10% ointment base has 
resulted in the disappearance of 
metastatic cutaneous adenocarci-
noma of the bowel without damage 
to normal skin (Klein et al. 1965). 
This observation, while limited in 
its application, is pertinent to a con-
sideration of using local 5-FU for 
palliation of recurrent or residual 
tumor. Up to 10% of 5-FU is ad-
sorbed by the gastrointestinal lining 
of the tumor segment (Cole, 1963) . 
Patients have tolerated up to 8 mg/ 
kg/day P.O. for up to six weeks 
with gastrointestinal side effects oc-
curring, on an average, in 18 days 
and hematologic toxicity in 21 days 
(Ellison, 1962). Although anti-tu-
mor effects have been seen (Cole, 
1963; Ellison, 1962; Kennedy and 
Theologides, 1961; Khung, 1965) , 
the virtues of local intraluminal 
instillation of 5-FU into tumor-
involved segments of bowel in 
prophylactic or adjuvant studies 
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have not been adequately explored. 
There are other agents becoming 
available, and reports of new drugs 
are awaited with interest. For ex-
ample, antibiotics which behave 
similarly to actinomycin D, such 
as chromomycin A., olivomycin, 
and mithramycin, which combine 
with DNA to impede RNA synthe-
sis (Ward, Reich, and Goldberg, 
1965) may show promise (Mayev-
sky, 1964; Akopliants, 1962). Stud-
ies of ethidium and daunomycin 
which have effects in common on 
purine metabolism (Ward et al., 
1965) may prove useful. 6-Azauri-
dine has been reported to produce 
objective improvement in one of 
three gastric and pancreatic carci-
noma patients for periods of four 
to five months (Welch et al., 1960). 
There is fairly extensive Japa-
nese literature regarding the clini-
cal efficacy of a variety of porphy-
rin derivatives (Fukuyama, Tsuji, 
and Nakagawara, 1963; Matsu-
bara et al., 1963; Tazaki, 1962; 
Tazaki and Fume, 1961). Hema-
toporphyrin mercury was reported 
to inhibit nucleic acid metabolism 
in stomach and intestine with an 
increased uptake of the drug in tu-
mor as compared with normal tis-
sue. This compound was said to 
produce objective and subjective 
improvement in several patients 
with gastrointestinal cancer (Fuku-
yama et al., 1963; Tazake, 1962; 
Tazaki and Fume, 1961 ) . Similar 
effectiveness was reported for a co-
b alt protoporphyrin preparation 
(Fukuyama et al., 1963; Matsubara 
et al., 1963). It is hoped that an 
evaluation of these reports will not 
take as long as those studies involv-
ing mitomycin C. 
In early clinical trials the toxicity 
which eventually blunts the initi al 
enthusiasm of extended trial is fre-
quently minimized. It was this type 
of experience with mitomycin C 
that delayed its entry into clinical 
practice. Much of the Japanese 
work with mitomycin C has been 
associated with its administration as 
an adjuvant at the time of surgery 
(Frank and Osterberg, 1960; Os-
ada, 1963; Shiba, 1963). A three-
year survival rate of 66% in com-
parison with a control of 30 % was 
found by Osada et al. ( 1963) in 
patients with gastric cancer who 
had undergone palliative surgical re-
section. Skepticism is in order, since 
one can also find reports indicating 
increased survival time in patients 
treated after gastrectomy with 
mechlorethamine, nitromin, sarko-
mycin, or carzinophilin (lshiyama, 
1965), P32 and TSPA (Osada, 
1963). Hoerr ( 1965) has found an 
11 % five-year survival rate in pal-
liative surgical resection for gastric 
cancer even in the absence of chem-
otherapy. Similar results have been 
obtained in untreated bile duct tu-
mors (Lippman, McDonald, and 
Longmire, 1959). Therefore, iso-
lated case reports of long term re-
sponses must be analyzed carefully, 
as they may be related to the se-
lection of a group of long-term sur-
vivors that are present in any given 
gastrointestinal tumor population. 
Varied approaches to dosage and 
timing of drug administration are 
important in any program of drug 
evaluation. This was dramatically 
demonstrated when the "old" drug, 
methotrexate, was used in a new 
way which led to the cure of chori-
ocarcinoma (Li, Hertz, and Spen-
cer, 1956) . Modified methotrexate 
regimens increased survival of chil-
dren with acute leukemia (Selawry 
and James, 1965; Acute Leukemia 
Group B, 1965) and are producing 
responses in bronchogenic carci-
noma (Ross and Selawry, 1965) 
and bowel cancer (Condit, Shnider, 
and Owens, 1962). The twice-a-
week administration of methotrex-
ate (0.25 mg/kg or 0.6 mg/kg) for 
gastrointestinal cancer is under 
study by the Eastern Solid Tumor 
Group, and the results are awaited 
with interest. 
As suggested by this review, 
much remains to be done in the 
chemotherapeutic approach to gas-
trointestinal cancer. The conserva-
tive use of 5-FU and alkylating 
agents have a place provided that 
severe toxicity is avoided. The sur-
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gical adjuvant use of 5-FU has a 
rational basis and its application to 
patients with nodal involvement or 
disease left behind is warranted. It 
is hoped that studies will continue 
that can lead to comparative infor-
mation pertinent to evidence of ob-
jective regression of disease and 
the practical reality of increased 
survival. 
Summary 
5-Fluorouracil (5-FU) is the best 
agent for the treatment of a ll gas-
trointestinal cancers but should be 
used with restraint, since severe 
toxicity does not guarantee in-
creased response or survival time. 
Experimental work suggests that 
glucose enhances cellular uptake of 
5-FU. Alkylating agents are defi-
nitely useful and occasionally pro-
duce long-term responses. Mitomy-
cin C shows activity but is not 
available. There are reports of re-
sponses to methotrexate, vinca al-
kaloids, and mithramycin, but their 
place in the management of gastro-
intestinal cancer is not established . 
The usefulness of alkylating agents 
or 5-FU as adjuvants to surgery is 
not clear, but evidence is accumu-
lating which supports the adjuvant 
use of 5-FU when disease is left 
behind. There is laboratory evi-
dence that anticoagulation can pre-
vent tumor recurrence, and this 
should be studied further. The best 
combination chemotherapy has not 
been determined. Regional chemo-
therapy offers a logical approach, 
but comparative data with systemic 
treatment are lacking, although 
techniques for protracted infusion, 
particularly of primary and second-
ary hepatic tumors, m ay justify its 
increased use. Wound washing with 
available contact tumoricidal agents 
is contraindicated, as it may in-
crease local recurrence. 
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CORRECTION: Vol. 3, No. 1 
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cluded in the period from 1955 to 
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most, however, were irradiated 
only. Stage II through IV patients 
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